Related references
Note: Only part of the references are listed.Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging
Douglas R. Lowy et al.
LANCET ONCOLOGY (2015)
Alternative dosage schedules with HPV virus-like particle vaccines
Margaret A. Stanley et al.
EXPERT REVIEW OF VACCINES (2014)
Early Impact of Human Papillomavirus Vaccination on Cervical NeoplasiauNationwide Follow-up of Young Danish Women
Birgitte Baldur-Felskov et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Long-term Study of a Quadrivalent Human Papillomavirus Vaccine
Daron Ferris et al.
PEDIATRICS (2014)
Virus-like particles for the prevention of human papillomavirus-associated malignancies
Joshua W. Wang et al.
EXPERT REVIEW OF VACCINES (2013)
Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial
Simon R. M. Dobson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010
Lauri E. Markowitz et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study
Amy Leval et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of GardasilTM in Adult Women
Joaquin Luna et al.
PLOS ONE (2013)
Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection
Igor A. Korostil et al.
VACCINE (2013)
Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium
Nadia Demarteau et al.
VACCINE (2013)
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study
Marc Brisson et al.
VACCINE (2013)
Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries
Karen Canfell et al.
VACCINE (2012)
Implementation of Human Papillomavirus Immunization in the Developing World
Mark A. Kane et al.
VACCINE (2012)
Human Papillomavirus Vaccines - Immune Responses
Margaret Stanley et al.
VACCINE (2012)
Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial
Mel Krajden et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults
Edson D. Moreira et al.
HUMAN VACCINES (2011)
Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in Vietnam A Cluster Randomized Noninferiority Trial
Kathleen M. Neuzil et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study
Julia M. L. Brotherton et al.
LANCET (2011)
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years
T. F. Schwarz et al.
VACCINE (2011)
Prospects for new human papillomavirus vaccines
Margaret Stanley
CURRENT OPINION IN INFECTIOUS DISEASES (2010)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjose et al.
LANCET ONCOLOGY (2010)
Immunogenicity Testing in Human Papillomavirus Virus-Like-Particle Vaccine Trials
John T. Schiller et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Recommendations for defining policies for papilloma virus vaccination in Mexico
Eduardo Lazcano-Ponce et al.
SALUD PUBLICA DE MEXICO (2009)
Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature
Tino F. Schwarz et al.
GYNECOLOGIC ONCOLOGY (2008)
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
Elmar A. Joura et al.
VACCINE (2008)
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
Gonzalo Perez et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
Sven-Eric Olsson et al.
VACCINE (2007)
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents - A randomized controlled trial
Keith S. Reisinger et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa et al.
BRITISH JOURNAL OF CANCER (2006)
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
Stan L. Block et al.
PEDIATRICS (2006)
Share Paper
